EIR Biopharma
Generated 5/9/2026
Executive Summary
EIR Biopharma is a private biotech company headquartered in San Diego, CA, with a therapeutic focus on modulating the Ephrin receptor system to treat neurodegenerative diseases, proliferative neovascular diseases (notably ophthalmic conditions), and cancer. Founded in 2019, the company has advanced to the 'Approved' stage, indicating that it has secured regulatory clearance for at least one product candidate. Its initial therapeutic area targets eye diseases linked to Ephrin receptor dysregulation, leveraging a platform that aims to halt aberrant angiogenesis and neurodegeneration. The company's approach addresses significant unmet needs in ophthalmology and oncology by precisely targeting receptor pathways implicated in disease progression.
Upcoming Catalysts (preview)
- Q3 2026FDA approval announcement for lead ophthalmic program85% success
- Q4 2026Initiation of Phase 2 trial for neurodegenerative indication60% success
- TBDStrategic partnership for oncology pipeline50% success
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)